Cognition Therapeutics Reports Completion of FDA Meeting on Zervimesine

What Happened

• On May 21, 2026, Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced it completed a meeting with the U.S. Food and Drug Administration to discuss zervimesine in patients with dementia with Lewy bodies (DLB) who experience psychosis. The company issued a press release about the meeting, which is furnished as Exhibit 99.1 to its Form 8-K (Item 8.01).

Key Details

• Date of announcement: May 21, 2026.
• Topic: FDA meeting regarding zervimesine for DLB patients with psychosis.
• Filing: Announcement was made via Form 8-K (Item 8.01) and press release is Exhibit 99.1.
• Ticker: Cognition Therapeutics, Inc. (CGTX).

Why It Matters

• Regulatory meetings with the FDA are material milestones for drug developers because they can clarify the regulatory pathway, data expectations, and next steps for clinical development.
• Investors should watch for follow-up disclosures (FDA feedback, meeting minutes, planned trials or protocol changes) that could affect zervimesine’s development timeline or value of the program.